Zacharon Pharma, Pfizer form R&D collaboration
Under the agreement, compounds will be developed using Zacharon’s platform for developing small molecule drugs targeting specific carbohydrate polymers or glycans. As per the terms of the agreement,
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.
The products include Kang Xi Eye Patch, KangXi Dental Ulcer Membrane, KangXi Anti-virus Mouthwash, KangXi Dental Ulcer Mouthwash, KangXi Snore Stopper, Kang Xi Periarthritis Shoulder Patch, KangXi Cervical